Mepyramine

Allergic diseases fall into the category of chronic diseases with a high global incidence, and antihistamines are one of the core medications for clinically relieving allergic symptoms. Mepyramine is a first-generation ethylenediamine antihistamine. By competitively blocking histamine H1 receptors, it inhibits histamine-mediated pathological reactions such as capillary dilation, increased permeability, and smooth muscle contraction. It can effectively alleviate discomforts including itching, redness, swelling, and runny nose caused by allergic rhinitis, urticaria, contact dermatitis and other diseases. It can also be used as a compound component in cold and cough preparations to relieve allergy-related symptoms, and the applicable population covers adult and pediatric patients without relevant contraindications.

At present, the overall global market size of antihistamines exceeds 8 billion US dollars. Among them, first-generation antihistamines still maintain stable demand in primary medical care, OTC market and compound preparation field due to their cost-effectiveness advantages. As a classic variety, mepyramine has an annual global demand of 100-ton level, and the market supply is dominated by generic drug manufacturers. There is no publicly verifiable segmented market size and growth rate data available at present.

The original developer of mepyramine is Bristol-Myers Squibb, with the original brand name Pyribenzamine, and the core compound patent expired in the 1970s. The originally marketed dosage forms mainly include tablets, creams and injections, with common specifications of 25mg and 50mg tablets and 2% concentration cream. The original product has been included in the FDA Reference Listed Drug Catalog. Up to now, there is no publicly announced A-status registration number of mepyramine API in China, and there is no domestically approved mepyramine single-agent or compound preparation variety marketed in China. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO can provide a full set of mepyramine impurity reference standards, most of which are available from stock. Spot orders paid before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the reference substance use needs of pharmaceutical enterprises in the whole process of R&D, quality research and production.